Strut vs Medvi

How we scoreOur 1 to 10 brand scores are our own editorial judgment. They are not aggregated from third-party review platforms and they are not the output of a scoring formula.

What a starting price isA starting price is the lowest figure a company lists for a category, not a quote. What you pay follows a clinician's review of your intake, and where a required membership or care plan sits alongside the medication we publish the two charges combined.

Reading a warning letterA close-out letter is FDA's record that it has evaluated a company's corrective actions, so the absence of one means the file is not closed on the public record, and nothing more than that.

Regulatory noticeRegulatory note (verified October 8, 2026): The FDA reviewed struthealth.com in December 2025 and, on February 20, 2026, issued Strut Health, LLC a warning letter, MARCS-CMS 721448. It raises two separate problems. Pictured product labels carry the "Strut" name, which the agency said represents Strut as the compounder of the semaglutide and tirzepatide products when it is not. The letter also quotes three claims from the site, among them "Generic Zepbound, Mounjaro", along with site copy naming semaglutide and tirzepatide as the active ingredient in the brand medications. Because compounded drugs hold no FDA approval, the FDA said wording of that kind implies one, and it cited misbranding under sections 502(a) and 502(bb) of the FD&C Act. The letter adds that introducing or delivering the products it identifies into interstate commerce is a prohibited act under section 301(a), that receiving them in interstate commerce and delivering or offering to deliver them also violates section 301(c), and that a compounded drug product must meet the conditions of section 503A or 503B of the FD&C Act to be exempt from certain requirements, including the new drug approval requirements. When we checked FDA's warning letter index for Strut Health, LLC on October 8, 2026 it showed no response letter and no close-out letter, so we treat the matter as open. Read the FDA letter

Regulatory noticeRegulatory note (verified October 8, 2026): On February 20, 2026 the FDA issued MEDVi, LLC a warning letter (MARCS-CMS 721455) citing misbranding under sections 502(a) and 502(bb) of the FD&C Act. Reviewing medvi.io in December 2025, the FDA said labels bearing "MEDVi" implied MEDVi compounds the drugs when it does not, and that site copy presenting the compounded drug as having the same active ingredient as Wegovy and Ozempic, and as Mounjaro and Zepbound, implied an FDA approval compounded drugs do not have. The letter adds that introducing or delivering the products it identifies into interstate commerce is a prohibited act under section 301(a), that receiving them in interstate commerce and delivering or offering to deliver them also violates section 301(c), and that a compounded drug product must meet the conditions of section 503A or 503B of the FD&C Act to be exempt from certain requirements, including the new drug approval requirements. When we checked FDA's warning letter index for MEDVi, LLC on October 8, 2026 it showed no response letter and no close-out letter entered against it, so the letter is not closed out on the public record. MEDVi states medvi.io is affiliate-operated rather than company-operated; we could not verify that, and the letter is addressed to MEDVi, LLC. Read the FDA letter